{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:57:13Z","timestamp":1715986633172},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T00:00:00Z","timestamp":1130371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Objectives:<\/jats:italic>\u2002Insulin\u2010like growth factor 1 (IGF\u20101) is an important growth and anti\u2010apoptotic factor for the cancer cells in several malignancies and in multiple myeloma recent studies support the hypothesis of a role for IGF\u20101 in disease progression; however, clinico\u2010biological relevance of IGF\u20101 was never studied in B\u2010cell chronic lymphocytic leukemia (CLL). <jats:italic>Patients and methods:<\/jats:italic>\u2002Using a quantitative sandwich immunoassay technique (ELISA) (Quantikine\u00ae, Human IGF\u20101 and IGFBP\u20103, R&amp;D Systems), we measured the concentration of IGF\u20101 and its major binding protein IGF\u2010binding protein 3 (IGFBP\u20103) in serum drawn at the time of diagnosis from 77 Binet stage A CLL patients. <jats:italic>Results:<\/jats:italic>\u2002Either IGF\u20101 or IGFBP\u20103 were significantly decreased compared with healthy age\u2010 and sex\u2010matched controls (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001 for both; Mann\u2013Whitney test). Serum levels of IGF\u20101 and IGFBP\u20103 paralleled each other (<jats:italic>P<\/jats:italic>\u2003=\u20030.002); in contrast, no significant correlation was found between serum levels of IGF\u20101 and clinico\u2010hematological variables including age (<jats:italic>P<\/jats:italic>\u2003=\u20030.253), sex (<jats:italic>P<\/jats:italic>\u2003=\u20030.270), Rai clinical substages (<jats:italic>P<\/jats:italic>\u2003=\u20030.140), lactate dehydrogenase (<jats:italic>P<\/jats:italic>\u2003=0.956), <jats:italic>\u03b2<\/jats:italic><jats:sub>2<\/jats:sub>\u2010microglobulin (<jats:italic>P<\/jats:italic>\u2003=\u20030.368), lymphocyte count (<jats:italic>P<\/jats:italic>\u2003=\u20030.703) and lymphocyte doubling time (LDT, <jats:italic>P<\/jats:italic>\u2003=\u20030.233). When correlation were attempted with circulating levels of angiogenic cytokines such as vascular endothelial growth factor (<jats:italic>P<\/jats:italic>\u2003=\u20030.971), basic fibroblastic growth factor (<jats:italic>P<\/jats:italic>\u2003=\u20030.695), angiogenin (<jats:italic>P<\/jats:italic>\u2003=\u20030.282) or adhesion molecules such as vascular cell adhesion molecule\u20101 (<jats:italic>P<\/jats:italic>\u2003=\u20030.318), intercellular adhesion molecule\u20101 (<jats:italic>P<\/jats:italic>\u2003=\u20030.883) and platelet endothelial cell adhesion molecule\u20101 (<jats:italic>P<\/jats:italic>\u2003=\u20030.772) similar results were found. Serum levels of IGF\u20101 were further evaluated as a dichotomous variable with respect to progression\u2010free survival (PFS), an endpoint surrogate for overall survival in early B\u2010cell CLL. The best separation of curves was seen with the cutoff point at the 75th percentile of IGF\u20101 levels (i.e., 93\u2003pg\/mL). Median PFS was 63\u2003months in the patient group with low IGF\u20101, compared with a median PFS of 40\u2003months in the remaining patients (<jats:italic>P<\/jats:italic>\u2003=\u20030.03). In the multivariate analysis performed including variables significant at univariate analysis [i.e. Rai substage (<jats:italic>P<\/jats:italic>\u2003=\u20030.002); LDT (<jats:italic>P<\/jats:italic>\u2003=\u20030.004), IGF\u20101 (<jats:italic>P<\/jats:italic>\u2003=\u20030.01)], only Rai substage retained prognostic significance (<jats:italic>P<\/jats:italic>\u2003=\u20030.006). However, after removing from analysis LDT (only six of 77 had an LDT\u2003&lt;\u200312\u2003months), either IGF\u20101 or Rai substage entered the model at a significant level (<jats:italic>P<\/jats:italic>\u2003=\u20030.03 and <jats:italic>P<\/jats:italic>\u2003=\u20030.01, respectively). <jats:italic>Conclusions:<\/jats:italic>\u2002IGF\u20101 did not correlate with markers of tumor burden or clinical status in CLL thus suggesting that levels of this cytokine do not reflect the intrinsic malignancy of disease. Results of the present study highlight, however, its involvement in mechanisms of disease progression in early CLL.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00553.x","type":"journal-article","created":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T12:36:33Z","timestamp":1130416593000},"page":"51-57","source":"Crossref","is-referenced-by-count":9,"title":["Serum insulin\u2010like growth factor is not elevated in patients with early B\u2010cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression"],"prefix":"10.1111","volume":"76","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Vitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Mirabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Digiesu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ribatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","article-title":"Insulin\u2010like growth factor (IGF)\u20101, IGF binding protein\u20103, and cancer risk: systematic review and meta\u2010regression analysis","volume":"363","author":"Ronehan AG","year":"2004","journal-title":"Lancet"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2001.01645.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000012052"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860410017260"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2741\/1625"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.4049\/jimmunol.151.4.1811","article-title":"Insulin and IGF\u20101 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226","volume":"151","author":"Freund GG","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250","article-title":"Insulin\u2010like growth factor is a growth and survival factor in human multiple myeloma cell lines","volume":"88","author":"Georgii\u2010Hemming P","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02364.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1406"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203781200"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602408"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05579.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Institute\u2010sponsored working guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson BD","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","article-title":"Bone marrow histologic pattern; the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases","volume":"64","author":"Rozman C","year":"1984","journal-title":"Blood"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01731.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08304.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2607"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V78.4.895.895","article-title":"Progression and survival studies in early chronic lymphocytic leukemia","volume":"78","author":"Molica S","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.256"},{"key":"e_1_2_5_26_2","first-page":"606a","article-title":"The serum \u03b2\n                  2\u2010microglobulin levels is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia","volume":"86","author":"Keating M","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1182\/blood.V88.11.4259.4259","article-title":"Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia","volume":"88","author":"Sarfati M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_28_2","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease\u2010progression in early, non\u2010smoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10384-1"},{"key":"e_1_2_5_30_2","first-page":"345","article-title":"A prospective study of plasma insulin\u2010like growth factor\u20101 and binding protein\u20103 and risk of colorectal neoplasia in women","volume":"9","author":"Giovannucci E","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.563"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2909"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01752.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated IgV (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin TJ","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle RN","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.181"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040857"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00553.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T04:34:46Z","timestamp":1695789286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00553.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00553.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00553.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,27]]}}}